

IN THE CLAIMS

Please amend the Claims as follows:

1. (original) A method of screening or testing for candidate anti-fungal compounds that impair ATP(CTP):tRNA nucleotidyltransferase enzyme (CCA1) function, comprising:
 - a) providing fungal CCA1;
 - b) providing one or more candidate compounds;
 - c) contacting said CCA1 with said one or more candidate compounds; and
 - d) determining the interaction of the candidate compound with said CCA1.
2. (original) A method according to claim 1 wherein the CCA1 comprises a fragment, a function-conservative variant, an active fragment or a fusion protein of CCA1.
3. (currently amended) A method according to ~~any one of~~ claim[[s]] 1 or 2, wherein the fungal CCA1 is from fungus of *Candida* or *Aspergillus* species.
4. (original) A modified eukaryotic cell(s) wherein the cell(s) expresses fungal CCA1 under the control of a heterologous promoter.
5. (original) The cell according to claim 4 which is a *C. albicans* cell.
6. (currently amended) The cell according to ~~any one of~~ claim[[s]] 4 or 5, wherein the CCA1 is homologous.
7. (currently amended) The cell according to ~~any one of~~ claim[[s]] 4 to 5, wherein the CCA1 comprises a fragment, a function-conservative variant, an active fragment or a fusion protein of CCA1.

8. (currently amended) A method of screening or testing for candidate anti-fungal compounds that impair ATP(CTP):tRNA nucleotidyltransferase enzyme (CCA1) function, comprising:
 - a) providing fungal CCA1 in a eukaryotic cell(s) as defined in ~~any one of claim[[s]] 4 to 7;~~
 - b) providing one or more candidate compounds;
 - c) contacting said eukaryotic cell(s) with said one or more candidate compounds; and
 - d) determining the interaction of the candidate compound with said CCA1 by assessing the effect on growth or viability of said cells.
9. (currently amended) A compound identified by the method of claim[[s]] 1, ~~2,3 or 8,~~ which impairs CCA1 function for use as an antifungal compound.
10. (original) A pharmaceutical composition comprising a CCA1 inhibitor and a pharmaceutically acceptable carrier.
11. (original) *Candida* or *Aspergillus* CCA1 as a specific target for antifungal compounds.
12. (canceled)
13. (canceled)
14. (currently amended) The ~~use~~ method according to claim ~~18 12 or 13~~ wherein the fungal infection is a topical, mucosal or systemic fungal infection.
15. (currently amended) The ~~use~~ method according to claim 14 wherein the topical or mucosal fungal infection is caused by species of *Candida* or the systemic fungal infection is caused by species of *Candida* or *Aspergillus*.

16. (currently amended) The ~~use~~ method according to any one of claim[[s]] ~~18 +2 to 15~~ wherein said compound impairs fungal CCA1 function to a greater extent than host CCA1 function.
17. (new) A compound identified by the method of claim 8, which impairs CCA1 function for use as an antifungal compound.
18. (new) A method for the treatment or prevention of fungal infections in a host, which comprises administering to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor.
19. (new) A method for the treatment or prevention of fungal infections in a subject who is immunosuppressed, which comprises the step of administering to the subject a therapeutically or prophylactically effective amount of a CCA1 inhibitor.
20. (new) The method according to claim 19 wherein the fungal infection is a topical, mucosal or systemic fungal infection.
21. (new) The method according to claim 19 wherein the topical or mucosal fungal infection is caused by species of *Candida* or the systemic fungal infection is caused by species of *Candida* or *Aspergillus*.
22. (new) The method according to 19 wherein said compound impairs fungal CCA1 function to a greater extent than host CCA1 function.